Human LPAR1 Full Length Protein (VLP)

AIDD‑Ready
Numéro de produit/spécification
Prix
Availability
Qté
LP1-H52P3-20ug
$620.00
In Stock - Delivery in 1-2 business days
LP1-H52P3-100ug
$1,235.00
In Stock - Delivery in 1-2 business days
LP1-H52P3-500ug (250ug X 2)
$4,305.00
In Stock - Delivery in 2-3 weeks
LP1-H52P3
Montant du produit :
$ 0
0
Ajouter au panier
Suggestion de nouveau produit Request Quote
Contact Us
Contact Us
Montant du produit:
$ 0
0
Ajouter au panier
  • Détails du produit
  • Affichage des données
  • Reviews & Citations
  • Important Statement
  • Resources
Application
  • Immunization
  • Cell based assay (FACS or functional assay)
  • Screening (ELISA)
Synonyms

EDG2, Gpcr26, LPA1, Mrec1.3, VZG1, edg-2, rec.1.3, vzg-1

Source

Human LPAR1 Full Length Protein (VLP) (LP1-H52P3) is expressed from human 293 cells (HEK293). It contains AA Ala 2 - Val 364 (Accession # Q92633).

Predicted N-terminus: Asp

Molecular Characterization

*The isotype control of empty/mock VLP (Cat. No. VLP-N5213) is sold separately and not included in protein, you can follow the link for product information.

Structure

Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

Synthesis Process

Envelope virus-like particles (eVLPs) are produced by co-expressing target membrane proteins with viral structural proteins in mammalian cells, enabling native embedding of membrane proteins into the lipid bilayer during VLP budding. This approach preserves authentic conformation, post-translational modifications, and orientation, while creating a completely detergent-free environment with repetitive multivalent display and strong immunogenicity making them ideal for immunization, binding assays in antibody discovery and screening (ELISA), and cell-based assays such as FACS, etc.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping and Storage

This product is supplied and shipped on dry ice.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:
  • The product MUST be stored at -70°C or lower upon receipt;
  • -70°C for 12 months under sterile conditions.

Introduction de fond

Lysophosphatidic Acid Receptor 1, a GPCR mediating fibrosis, vasoconstriction, and neuropathic pain. It is a genetically and pharmacologically validated target for Idiopathic Pulmonary Fibrosis (IPF) and Systemic Sclerosis. Antagonists aim to halt fibroblast migration and collagen deposition in progressive fibrotic diseases.